XNW5004 is a rationally designed, highly selective and potent EZH2 inhibitor with potentially best-in-class efficacy and safety profile demonstrated in a Phase I trial in patients with lymphoma. The combination trial is an open label, single-arm Phase Ib/II study designed to establish the RP2D dose of XNW5004 in combination with KEYTRUDA^® and to evaluate the safety and efficacy of XNW5004 in combination with KEYTRUDA^® for patients with advanced solid tumors.

“We are extremely pleased to collaborate with MSD, a well-established world leader and pioneer in the field of cancer immunology,” said Jing Qiang, Chairmen of Evopoint. “Our promising drug candidate, XNW5004, has demonstrated a potential additive benefit when given in combination with anti-PD-1 therapy in animal models. Based on the mechanism of action of EZH2 in tumor cells and tumor microenvironment, the observations in our preclinical studies, and the excellent efficacy and safety profile of XNW5004 exhibited in the Phase I study, we are very optimistic that XNW5004 in combination with KEYTRUDA^® may significantly improve the clinical outcome in patients with advanced solid tumors, potentially providing meaningful clinical benefits to those patients for improving their lives.”

Under the terms of the agreement, Evopoint will sponsor the Phase Ib/II trial and MSD will supply KEYTRUDA^®. Evopoint maintains the global rights to XNW5004.

KEYTRUDA^® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA